首页> 外文OA文献 >Synthesis And Characterization Of Brain Penetrant Prodrug Of Neuroprotective D264: Potential Disease Modifying Treatment Agent For Parkinsonu27s Disease
【2h】

Synthesis And Characterization Of Brain Penetrant Prodrug Of Neuroprotective D264: Potential Disease Modifying Treatment Agent For Parkinsonu27s Disease

机译:神经保护D264脑渗透前体药物的合成与表征:帕金森病潜在疾病改良治疗药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Parkinsonu27s disease (PD) is a complex neurodegenerative disorder with progressive loss of dopamanergic neurons in the substantia nigra region of the brain and accumulation of intracytoplasmic inclusions called `Lewy bodiesu27. PD is characterized by tremors, rigidity, slowness of movement, bradykinesia and postural imbalances. Although the etiology of PD is not well understood, it is well established that oxidative stress, mitochondrial dysfunction, alpha-synuclein aggregation play a central role in the pathogenesis of PD. Current treatment methods are based on symptomatic relief without addressing the underlying pathophysiological factors responsible for the disease. It is important to develop therapies which can address these complex pathogenesis of the disease process and providing symptomatic relief as well. Towards development of novel multifunctional dopamine D2/D3 agonist drugs for the treatment of Parkinsonu27s disease (PD), D-264 was previously synthesized in our lab. D-264, a potent D3 preferring agonist, is one of our lead compounds which showed high neuroprotection in MPTP u26 Lactacystin PD animal models. However, this drug seems to have minimal brain penetration. In order to further enhance the efficacy and bio-availability of D-264 in the brain, we have designed a cysteine based D-264 prodrug as a substantial amount of research points out an important role of antioxidants such as L-cysteine in reducing the oxidative stress associated with PD .To this end, we have evaluated the ex vivo hydrolysis pattern of synthesized prodrug to yield active D-264 in brain u26 plasma solutions using RP-HPLC. In order to evaluate the efficiency of prodrug in crossing blood-brain barrier, in vivo brain penetration studies were performed and efficiency of hydrolysis was quantified using RP-HPLC. Further, DPPH based anti-oxidant assay was performed to evaluate the anti-oxidant property of prodrug. Details of prodrug design, synthesis and pharmacological evaluation will be presented. This work is supported by NS047198 (AD)
机译:帕金森氏病(PD)是一种复杂的神经退行性疾病,在大脑的黑质区域内多巴曼能神经元逐渐丧失,并被称为“路易体”的胞质内含物积聚。 PD的特点是震颤,僵硬,运动缓慢,运动迟缓和姿势不平衡。尽管对PD的病因尚不十分了解,但已经确定氧化应激,线粒体功能障碍,α-突触核蛋白聚集在PD的发病机理中起着重要作用。当前的治疗方法基于症状缓解,而没有解决造成该疾病的潜在病理生理因素。重要的是开发能够解决疾病过程的这些复杂发病机理并提供症状缓解的疗法。为了开发新型的用于治疗帕金森氏病(PD)的多功能多巴胺D2 / D3激动剂,D-264是我们实验室中先前合成的。 D-264是一种强效的D3激动剂,是我们的先导化合物之一,在MPTP乳腺乳杆菌PD动物模型中显示出高神经保护作用。但是,这种药物似乎对大脑的渗透很小。为了进一步增强D-264在大脑中的功效和生物利用度,我们设计了一种基于半胱氨​​酸的D-264前药,因为大量研究指出了抗氧化剂(例如L-半胱氨酸)在降低脑组织中的重要作用。为此,我们使用RP-HPLC评估了合成前药的离体水解模式,以在脑血浆溶液中产生活性D-264。为了评估前药在穿越血脑屏障中的效率,进行了体内脑渗透研究,并使用RP-HPLC定量了水解的效率。此外,进行基于DPPH的抗氧化剂测定以评估前药的抗氧化性质。将介绍前药设计,合成和药理学评估的详细信息。 NS047198(AD)支持这项工作

著录项

  • 作者

    Dholkawala Fahd Shamoon;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号